Boehringer Ingelheim To Keep Supplying U.S.' Foot And Mouth Disease Vaccine Bank
The U.S. Department of Agriculture has selected Boehringer Ingelheim to continue supplying antigen for a vaccine bank that protects U.S. livestock from a potential outbreak of foot-and-mouth disease (FMD).
Boehringer Ingelheim will build on work it has done since receiving a contract in 2020 to supply the National Animal Vaccine and Veterinary Countermeasures Bank.
Since receiving that contract, Boehringer Ingelheim has been supplying doses of foot-and-mouth disease vaccine antigen concentrate to the bank, a strategic reserve of frozen vaccine antigen concentrate that Boehringer Ingelheim could quickly formulate into finished vaccine in the event of a disease outbreak.
The company could supply those doses in a hurry to U.S. livestock producers in an outbreak of foot-and-mouth disease, a highly contagious viral disease that affects cattle, pigs, sheep, goats and other animals with divided hooves.
"As a company dedicated to the well-being of animals and people, we are honored to help protect U.S. livestock from an outbreak that would have devastating consequences," said Steve Boren, vice president of the Boehringer Ingelheim U.S. livestock business.
To view the complete report, click here.